Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Contrast Media Mol Imaging. 2020 Sep 14;2020:3216179. doi: 10.1155/2020/3216179. eCollection 2020.
Urachal carcinoma is a rare urological malignancy. Use of F-FDG PET/CT in urological oncology has developed slowly because of the urinary elimination of F-FDG. We investigated whether delayed postdiuretic F-FDG PET/CT could be used for diagnosing urachal carcinoma.
This retrospective study included 6 patients who underwent delayed postdiuretic F-FDG PET/CT for the evaluation of urachal carcinoma. The delayed postdiuretic PET/CT parameters and clinical characteristics of urachal carcinoma were investigated.
There was no significant difference in the SUVmax between the primary tumors and the urine in the bladder before delayed diuresis (25.4 ± 19.5 vs. 42.9 ± 31.1, =0.18). However, the SUVmax of the primary tumors was significantly higher than the SUVmax of urine after delayed diuresis (25.4 ± 19.5 vs. 3.5 ± 1.6, =0.002). Diuretic F-FDG PET/CT was positive in all patients when compared with normal liver tissues or urine after delayed diuresis. The SUVmax, TLR, and TUR of the primary tumors were 25.4 (range: 7.2-58.9), 7.0 (range: 1.8-14.7), and 6.8 (range: 3.8-11.3), respectively. Delayed postdiuretic F-FDG PET/CT had a negative predictive value of 100% (5/5) for predicting lymph node metastasis. One patient received chemotherapy after radical resection of urachal carcinoma because F-FDG PET/CT found lung metastases, and one patient only received chemotherapy because PET/CT found peritoneal and skeletal metastases.
Delayed postdiuretic F-FDG PET/CT is a useful tool for the preoperative evaluation of urachal carcinoma. F-FDG PET/CT may improve clinical decision making and management of urachal carcinomas.
脐尿管癌是一种罕见的泌尿系统恶性肿瘤。由于 F-FDG 会经尿液排泄，因此 F-FDG PET/CT 在泌尿系统肿瘤学中的应用发展缓慢。我们研究了利尿剂后延迟 F-FDG PET/CT 是否可用于诊断脐尿管癌。
本回顾性研究纳入了 6 例因脐尿管癌接受利尿剂后延迟 F-FDG PET/CT 检查的患者。研究了脐尿管癌的延迟利尿剂后 PET/CT 参数和临床特征。
在延迟利尿前，原发肿瘤的 SUVmax 与膀胱内尿液无显著差异（25.4 ± 19.5 比 42.9 ± 31.1，=0.18）。然而，延迟利尿后原发肿瘤的 SUVmax 明显高于尿液（25.4 ± 19.5 比 3.5 ± 1.6，=0.002）。与延迟利尿后的正常肝组织或尿液相比，利尿剂后 F-FDG PET/CT 检查在所有患者中均为阳性。原发肿瘤的 SUVmax、TLR 和 TUR 分别为 25.4（范围：7.2-58.9）、7.0（范围：1.8-14.7）和 6.8（范围：3.8-11.3）。延迟利尿剂后 F-FDG PET/CT 对预测淋巴结转移的阴性预测值为 100%（5/5）。1 例患者在接受根治性切除术后因 F-FDG PET/CT 发现肺转移而接受化疗，1 例患者仅因 PET/CT 发现腹膜和骨骼转移而接受化疗。
延迟利尿剂后 F-FDG PET/CT 是术前评估脐尿管癌的有用工具。F-FDG PET/CT 可能改善对脐尿管癌的临床决策和管理。
